Biohaven (BHVN) Tax Provisions (2021 - 2026)
Biohaven (BHVN) posted Tax Provisions of $272000.0 for Q1 2026, down 22.51% sequentially from $351000.0 in Q4 2025, and down 55.34% YoY from $609000.0 in Q1 2025.
Analysis
Biohaven (BHVN) Tax Provisions (2021 - 2026) Analysis & Trends
Biohaven has reported Tax Provisions for 6 years, with the latest figure at $272000.0 in Q1 2026.
- Quarterly Tax Provisions fell 55.34% year-over-year to $272000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.1 million (up 42.58% YoY) and the FY2025 annual result came in at $1.4 million, up 96.19% from the prior year.
- Tax Provisions declined to $272000.0 in Q1 2026 per BHVN's latest filing, from $351000.0 in the prior quarter.
- Over five years, Tax Provisions peaked at $7.3 million in Q1 2022 and troughed at -$14.1 million in Q4 2022.
- A 5-year average of $88470.6 and a median of $272000.0 in 2026 frame the typical range for Tax Provisions.
- The sharpest annual moves came in 2022 and 2025: Tax Provisions tumbled 675.62% in 2022, then surged 631.25% in 2025.
- Over 5 years, Tax Provisions stood at -$14.1 million in 2022, then jumped by 91.43% to -$1.2 million in 2023, then soared by 103.96% to $48000.0 in 2024, then soared by 631.25% to $351000.0 in 2025, then decreased by 22.51% to $272000.0 in 2026.
- According to Business Quant data, Tax Provisions over the past three periods registered $272000.0, $351000.0, and $221000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 292.00 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 230.90 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | -59.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 15.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 75.45 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 13.31 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 1.90 Mn |
| 10 | Biohaven | 2.37 Bn | 2.10 Bn | - | 391,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 391,000.00 |
| Mar 31, 2026 | 272,000.00 |
| Dec 31, 2025 | 351,000.00 |
| Sep 30, 2025 | 221,000.00 |
| Jun 30, 2025 | 261,000.00 |
| Mar 31, 2025 | 609,000.00 |
| Dec 31, 2024 | 48,000.00 |
| Sep 30, 2024 | -59,000.00 |
| Jun 30, 2024 | 177,000.00 |
| Mar 31, 2024 | 569,000.00 |
| Dec 31, 2023 | -1.21 Mn |
| Sep 30, 2023 | -3.29 Mn |
| Jun 30, 2023 | 2.18 Mn |
| Mar 31, 2023 | 939,000.00 |
| Dec 31, 2022 | -14.14 Mn |
| Sep 30, 2022 | 1.22 Mn |
| Jun 30, 2022 | 6.11 Mn |
| Mar 31, 2022 | 7.26 Mn |
| Dec 31, 2021 | 2.46 Mn |
| Sep 30, 2021 | -1.13 Mn |